Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S.

Amylyx Pharmaceuticals Inc. and Gubra A/S have established a collaboration for the development of a novel long-acting GLP-1 receptor antagonist.